Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Michigan |
---|---|
Information provided by: | University of Michigan |
ClinicalTrials.gov Identifier: | NCT00262405 |
Open label trial of zileuton compared to azathioprine/prednisone for patients with idiopathic pulmonary fibrosis. Study subjects will undergo a detailed clinical, radiographic, and physiologic assessment at baseline. Subjects will be monitored off treatment for three months for changes in symptoms and physiology. Subjects will then be randomized to six months of treatment with zileuton or azathioprine/prednisone. The primary endpoint of this trial is change in LTB4 levels in bronchoalveolar lavage fluid following six months of treatment. Secondary endpoints are progression free survival, change in dyspnea, change in quality of life, and change in physiology.
Condition | Intervention | Phase |
---|---|---|
Idiopathic Pulmonary Fibrosis |
Drug: zileuton Drug: azathioprine/prednisone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis |
Ages Eligible for Study: | 35 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Physiologic Criteria:
Laboratory Criteria:
United States, Michigan | |
University of Michigan | |
Ann Arbor, Michigan, United States, 48109 |
Principal Investigator: | Galen B Toews, MD | University of Michigan |
Study ID Numbers: | 1995-0304 |
Study First Received: | September 12, 2005 |
Last Updated: | September 11, 2006 |
ClinicalTrials.gov Identifier: | NCT00262405 |
Health Authority: | United States: Institutional Review Board |
Prednisone Lung Diseases, Interstitial Azathioprine Respiratory Tract Diseases Fibrosis |
Zileuton Hamman-Rich syndrome Lung Diseases Pulmonary Fibrosis Leukotriene Antagonists |
Antimetabolites Anti-Inflammatory Agents Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Hormones Pathologic Processes Sensory System Agents Therapeutic Uses |
Anti-Inflammatory Agents, Non-Steroidal Analgesics Antineoplastic Agents, Hormonal Enzyme Inhibitors Glucocorticoids Immunosuppressive Agents Pharmacologic Actions Lipoxygenase Inhibitors Analgesics, Non-Narcotic Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |